Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. FIRST AMENDMENT TO COMPANION DIAGNOSTICS AGREEMENTCompanion Diagnostics Agreement • January 27th, 2014 • Epizyme, Inc. • Pharmaceutical preparations
This First Amendment (“Amendment”) shall be effective as of this 31st day of May 2013 (“Amendment Effective Date”), by and between Epizyme, Inc., having a place of business at 400 Technology Square, 4th Floor, Cambridge, Massachusetts 02139, U.S.A. (“Epizyme”) and Eisai Co., Ltd., having a place of business at Koishikawa 4-6-10, Bunkyo-ku, Tokyo 112-8088, Japan (individually, “Eisai” and collectively with Epizyme, “Pharmaceutical Partners”), on the one side, and Roche Molecular Systems, Inc., having a place of business at 4300 Hacienda Drive, Pleasanton, California 94588, U.S.A. (“RMS”), on the other side, as an amendment to the Companion Diagnostics Agreement, dated 18th December 2012 (“Agreement”). Capitalized terms used in this Amendment and not defined in this Amendment shall have the meanings ascribed to them in the Agreement.
AMENDMENT TO COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • January 27th, 2014 • Epizyme, Inc. • Pharmaceutical preparations
This Amendment to the Collaboration and License Agreement (this “Amendment”) is dated as of October 8, 2013 (the “Amendment Effective Date”) by and among Epizyme, Inc. (“EPIZYME”), Celgene International Sàrl (“CELGENE”) and Celgene Corporation (“PARENT”). Each of EPIZYME and CELGENE may be referred to herein as a “Party” or EPIZYME and CELGENE may be referred to herein collectively as the “Parties.”
